Sandoz Recalls Orphenadrine Citrate Tablets for Dissolution Failures
Sandoz Inc. is recalling Orphenadrine Citrate Extended Release Tablets because they failed dissolution specifications during stability testing.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Sandoz Inc. is recalling Orphenadrine Citrate Extended Release Tablets, 100 mg, in 100-count and 1000-count bottles. The recall involves approximately 781,000 tablets distributed nationwide. The affected lots are DM1316 and DM1318, both with an expiration date of 05/16.
The recall was initiated because the product was found to be out of specification (OOS) during stability testing, specifically regarding dissolution. This means the tablets may not release the medication as intended.
Consumers with these specific lot numbers should stop using the medication and contact their healthcare provider or pharmacist for guidance. The FDA has classified this as a Class III recall, indicating that the violation is not likely to cause adverse health consequences.
The recalled product
- Product
- ORPHENADRINE CITRATE (ORPHENADRINE CITRATE)
- Brand
- ORPHENADRINE CITRATE
- Manufacturer
- Sandoz Inc
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 781,000
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # DM1316
- Exp. 05/16 Lot # DM1318
- Exp. 05/16
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ORPHENADRINE CITRATE
- HighFDA Recalls Orphenadrine Citrate Tablets Due to Nitrosamine Impurity
FDA (Drugs) · 2022-04-13
Same manufacturer · Sandoz Inc
See all →- LowFocalin XR 5mg capsules carry incorrect or missing lot and expiry
FDA (Drugs) · 2026-06-24
- ModerateCyclophosphamide injection vials recalled after a transportation temperature excursion
FDA (Drugs) · 2025-09-24
- ModerateCiprofloxacin and dexamethasone otic suspension recalled following temperature abuse
FDA (Drugs) · 2025-09-17
- SevereBuffered penicillin G potassium vials may actually contain cefazolin for injection
FDA (Drugs) · 2025-07-09
- SevereSandoz cefazolin cartons contained vials labeled as penicillin G potassium
FDA (Drugs) · 2025-07-09
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17